Company news
Absci Corporation (NASDAQ:ABSI) news
Every Absci Corporation press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026
July 14, 2026
Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors
June 24, 2026
MindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ: ABSI) and a Leading AI Compute Provider on Jones AI Day Panel on the...
June 12, 2026
Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results
May 7, 2026
Absci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026
April 23, 2026
Absci to Participate in the 25th Annual Needham Virtual Healthcare Conference
April 8, 2026
Absci Launches ABS-201 Endometriosis Advisory Board with Leading Experts from Yale, UCSF, Duke, and the Mayo Clinic
March 24, 2026
Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results
March 24, 2026
Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer
March 3, 2026
Absci to Report Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results on March 24, 2026
February 24, 2026
Absci to Participate in the 44th Annual J.P. Morgan Healthcare Conference
December 16, 2025
Absci Reports New Human Ex Vivo Data Demonstrating That ABS-201™ Stimulates Hair Growth and Regenerates Stem Cell Niche to Potentially Re...
December 11, 2025
Absci and U.S. Soccer Legend Landon Donovan Partner to Champion the Patient Voice in Hair Loss Research
December 10, 2025
Absci Announces First Participants Dosed in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenetic Alopecia
December 4, 2025
Absci Reports Business Updates and Third Quarter 2025 Financial and Operating Results
November 12, 2025
Absci to Report Business Updates and Third Quarter 2025 Financial and Operating Results on November 12, 2025
October 29, 2025
Absci to Participate in Upcoming Investor Conferences
October 27, 2025
Absci to Host KOL Seminar on ABS-201 Androgenetic Alopecia Program on December 11, 2025; Announces Accelerated Initiation of Phase 1/2a T...
October 15, 2025
Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD
September 11, 2025
Absci Expands ABS-201 Scientific Advisory Board with Addition of Leading Dermatology Experts Dr. Rodney Sinclair and Dr. David Goldberg
August 25, 2025
Absci Reports Business Updates and Second Quarter 2025 Financial and Operating Results
August 12, 2025
Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target
August 7, 2025
Absci to Report Business Updates and Second Quarter 2025 Financial and Operating Results on August 12, 2025
July 30, 2025
Absci Announces Proposed Public Offering of Common Stock
July 24, 2025
Absci Announces Pricing of Public Offering of Common Stock
July 24, 2025
Absci Appoints Biopharma Leader Mary Szela to Board of Directors
July 7, 2025
Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treat...
May 13, 2025
Absci Reports Business Updates and First Quarter 2025 Financial and Operating Results
May 13, 2025
Absci to Report Business Updates and First Quarter 2025 Financial and Operating Results on May 13, 2025
April 14, 2025
Absci Reports Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results
March 18, 2025
Absci to Participate in the KeyBanc Capital Markets Healthcare Forum
March 4, 2025
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 4, 2025
Absci to Report Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results on March 18, 2025
March 4, 2025
Absci to Participate in the TD Cowen 45th Annual Health Care Conference
February 18, 2025
Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference
January 22, 2025
Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery
January 10, 2025
Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery
January 8, 2025
Absci and Invetx Partner to Bring Generative AI Drug Creation Platform to Animal Health
January 6, 2025
Absci to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
January 2, 2025
Absci Highlights Progress and Updates Across Proprietary Pipeline and Leading AI Platform at 2024 R&D Day
December 12, 2024
Absci to Participate in the 36th Annual Piper Sandler Healthcare Conference
November 21, 2024
Absci Reports Business Updates and Third Quarter 2024 Financial and Operating Results
November 12, 2024
Absci to Host R&D Day on December 12, 2024
November 7, 2024
Absci and Twist Bioscience Collaborate to Design Novel Antibody using Generative AI
October 31, 2024
Absci to Report Business Updates and Third Quarter 2024 Financial and Operating Results on November 12, 2024
October 15, 2024
Absci Reports Business Updates and Second Quarter 2024 Financial and Operating Results
August 14, 2024
Absci Collaborates with Global Cancer Center to Discover Novel Therapeutics Using Generative AI
August 12, 2024
Absci to Report Business Updates and Second Quarter 2024 Financial and Operating Results on August 14, 2024
July 10, 2024
Absci to Participate in the Morgan Stanley 3rd Annual Life Sciences AI Summit
June 12, 2024
Absci to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
May 28, 2024